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health states. The scenarios were (A) “good” function with no
movement disorders [extrapyramidal symptoms]; (B) “good”
function with movement disorders; (C) “bad” function with no
movement disorders; (D) “bad” function with movement disor-
ders; (E) hospitalised relapse with no movement disorders; (F)
hospitalised relapse with movement disorders; (G) post-hospi-
talisation with no movement disorders; and (H) post-hospitali-
sation with movement disorders. A utility value between zero
(death) and one (perfect health) for each scenario was calculated
using the AQoL. RESULTS: The mean (±SD) utility values for
each health state scenario from the general population perspec-
tive were [n = 87]: (A) 0.68 ± 0.27; (B) 0.48 ± 0.25; (C) 0.17 ±
0.24; (D) 0.11 ± 0.21; (E) 0.03 ± 0.23; (F) 0.01 ± 0.20; (G) 0.57
± 0.27; and (H) 0.46 ± 0.24. Those for caregivers were [n = 7]:
(A) 0.34 ± 0.18; (B) 0.22 ± 0.22; (C) 0.10 ± 0.20; (D) 0.11 ±
0.22; (E) 0.03 ± 0.10; (F) 0.03 ± 0.13; (G) 0.25 ± 0.22; and (H)
0.31 ± 0.25. The mean (±SD) utility values for the caregivers
themselves were [n = 7]: (A) 0.65 ± 0.14; (B) 0.54 ± 0.29; (C)
0.46 ± 0.26; (D) 0.41 ± 0.25; (E) 0.23 ± 0.25; (F) 0.08 ± 0.09;
(G) 0.55 ± 0.21; and (H) 0.43 ± 0.22. There was a trend for
higher utility values to be associated with better outcomes and
lower utility values to be associated with poorer outcomes.
CONCLUSIONS: The trends in the utility values were consis-
tent between the general population and caregivers. There was
a concomitant decrease in the quality of life of a caregiver with
increasing severity of the patient’s condition.
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OBJECTIVES: To present preliminary baseline data on patient
and family burden associated with Attention-Deﬁcit/Hyperactiv-
ity Disorder (ADHD) symptoms in German patients enrolled in
the ADORE study (Attention Deﬁcit Hyperactivity Observa-
tional Research in Europe). METHODS: ADORE is an ongoing
24 month, pan-European, prospective, observational study to
describe the relationship between treatment regimen prescribed
and quality of life in ADHD. Only those patients were docu-
mented that had not formally been diagnosed with ADHD
before. RESULTS: In total, 392 patients with a mean age of 8.7
(SD 2.1) years with inattentive/impulsive/hyperactive symptoms
were enrolled, of which 300 (77%) were male. Patient
birth/maternity problems included: smoking in 57 cases (15%),
maternal drug/alcohol abuse in 8 cases (2%), 37 patients (9%)
were born prematurely, 23 (6%) had low birth weight, and in
79 cases (20%) other birth/maternity problems were experi-
enced. Past history of inattentive/impulsive/hyperactive symp-
toms in the immediate family was reported for 171 patients
(44%), 29 cases (7%) in the extended family, and 13 cases (3%)
in both the immediate and extended family. A total of 130
mothers (33%) and 41 fathers (10%) experienced emotional
problems due to the patient’s symptoms. During the last 6-
months, 47 (12%) patients experienced some exclusions from
school lessons, 48 (12%) were in special educational programs,
and 30 (8%) were requested to change to a special needs school.
Thirty-six patients/families (9%) had contact with social ser-
vices, 7 (2%) had contact with the police. Over the last 4 weeks,
134 patients (34%) were involved in bullying, as the victim (N
= 49; 13%), the bully (N = 58; 15%), or both (N = 27; 7%).
Seven patients (2%) reported current tobacco use/abuse, 2 (<1%)
cannabis use/abuse, and 4 (1%) alcohol use/abuse. CONCLU-
SIONS: Baseline data suggest that ADHD symptoms are associ-
ated with a considerable burden on patients and families in terms
of school behavior, social activities, and emotional problems.
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OBJECTIVES: The aim of this study was to investigate whether
the use of conventional antipsychotics and newer atypical
antipsychotic drugs, such as olanzapine, risperidone or quetiap-
ine, is associated with an increased incidence of diabetes melli-
tus. METHODS: Data were obtained from the PHARMO
Record Linkage System comprising pharmacy records and hos-
pitalisations of all 950,000 community-dwelling inhabitants of
18 geo-demograﬁc deﬁned areas in the The Netherlands from
1991 until 2003. In a nested case-control study among users of
antipsychotic drugs, 1365 cases and 8143 controls with a hos-
pitalisation for diabetes or who were using antidiabetic drugs
(index date) matched on age, sex, and calendar year were
selected. Use of antipsychotic drugs among cases and controls
was determined over three months prior to the index date. Con-
ditional logistic regression was performed to estimate odds ratios
and 95% conﬁdence intervals (CI). RESULTS: Compared with
no antipsychotic use, use of olanzapine, conventional antipsy-
chotic drug and other newer atypical antipsychotics, but not
risperidone (OR adjusted 1.17 (95%CI: 0.61–2.23), are associ-
ated with a signiﬁcant increase in the risk of diabetes (OR
adjusted 2.52 (95%CI: 1.21–5.26), 3.22 (95%CI: 2.70–3.84)
and 2.22 (95%CI: 1.05–4.69), respectively). Cases and controls
who used conventional antipsychotic drugs were older than the
other atypical antipsychotic drug groups. CONCLUSIONS: Our
results suggest that use of conventional antipsychotics, olanzap-
ine, and other newer antipsychotics (clozapine, sertindole and
remoxipride), but not risperidone, was consistently associated
with an increased risk of diabetes. It is therefore important to
stress that the metabolic consequences of antipsychotic drug
therapy should be considered by the treating physicians.
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OBJECTIVE: This is the ﬁrst study to estimate the impact of dia-
betes on the probability of working and weekly work hours for
Canadian with insulin dependent diabetes (IDDM) and non-
insulin dependent diabetes (NIDDM) and diabetes related
comorbidities/complications. METHODS: Two-part model were
performed to predict the weekly work hours (after adjusting for
other chronic disorders and socio-demographic) of diabetics
among respondent to the Canadian Community Health Survey
2001. Logistics regression and multiple OLS analyses were used
to predict the probability of employment and weekly work
hours. RESULTS: Women and men with IDDM had lower prob-
ability of having job by 10% and 5%, respectively compared
with healthy groups. These probabilities were smaller for women
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and men with diabetes-related comorbidities/complications by
13% and 5% compared to IDDM without diabetes reated
comorbidities/complications. The probability of working for
women and men with NIDDM also were 7% and 2% less than
women and men without this disorder. Similarly, these proba-
bilities were even smaller for women and men with NIDDM
related comorbidities/complications by 2% compared with
NIDDM without diabetes reated comorbidities/complications
(all at p-values <0.05). The predicted weekly work hours for
women and men without diabetes were 29 and 41 hours, with
IDDM were 18 and 30, with IDDM and comorbidities/compli-
cations were 13 and 23, with NIDDM were 21 and 35 hours
and ﬁnally with NIDDM and related comorbidities/complica-
tions were 17 and 30, respectively. CONCLUSIONS: The effect
of diabetes and its related comorbidities especially for men with
NIDDM and related comorbidities/complications on the proba-
bility of unemployment and predicted weekly work hours in
Canada are substantial. The results of this study have implica-
tions for cost-effectiveness of diabetes control and may facilitate
studies of the health burden of diabetes for the prevention and
treatment of diabetes and thus increase the labor productivity.
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OBJECTIVES: A 24-month randomised, open-label parallel
group study in type 2 diabetes patients compared the safety and
efﬁcacy of biphasic insulin aspart (BIAsp30/70) and biphasic
human insulin (BHI30/70) injected twice daily before meals.
Major hypoglycaemic episodes were reduced with BIAsp30/70
(annual rate 4.1%) versus BHI30/70 (annual rate 15.5%) and
were signiﬁcantly lower in the second study year (p = 0.04). Gly-
caemic control did not differ between groups. A peer-reviewed,
validated model projected the impact of the different rates of
major hypoglycaemia events on long-term health economic out-
comes in multinational settings. METHODS: The CORE Dia-
betes model employs standard Markov/Monte Carlo simulation
techniques to describe long-term incidence and progression of
diabetes-related complications. Transition probabilities were
derived from major diabetes studies. The clinical effects of the
comparators were derived from the trial described. The analysis
was performed in multinational settings using published country-
speciﬁc costs, health care resource utilization, clinical data, and
recommended discount rates. A lifetime horizon and payer per-
spective was taken. Only direct costs were considered. Sensitiv-
ity analyses was performed. RESULTS: Discounted
quality-adjusted life years (QALY) were improved by 0.15–0.22
years with BIAsp30/70 versus BHI30/70 depending on country
speciﬁc discount rates. Increases in lifetime costs were seen with
BIAsp30/70 in all settings. Costs per QALY were DKK61,922,
9784€, 12,840€, NOK38,911€, 14,068€, SEK76,495€, and
£6,585 in the Danish, Finnish, German, Norwegian, Spanish,
Swedish, and UK setting respectively. Results were most sensi-
tive to assumptions regarding major hypoglycaemia rates, mor-
tality following major hypoglycemic events, HbA1c changes and
to the relative costs of BIAsp30/70 versus BHI30/70. CON-
CLUSIONS: Treatment with BIAsp30/70 was projected to result
in additional QALYS and reduced health care costs associated
with major hypoglycaemic events versus treatment with
BHI30/70. The higher acquisition costs of BIAsp30/70 led to
increased overall costs, but the incremental cost/QALY fell
within the range generally considered to be cost-effective in each
country.
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OBJECTIVE: We report on the results of proof-of-concept study
designed to encourage patient adherence to treatment guidelines
and allow German physicians treating patients with Type-2 dia-
betes with nateglinide to gain patient feedback using an entirely
wireless design. Subject Sample: 60 patients and 5 physicians
agreed to participate in the study. METHODS: Using mobile
communications devices, patients reported on their medication-
taking experience and clinical values, including blood glucose
levels, according to a clinical protocol have ﬁve (5) patient
reporting events during the study period of 14 days. This infor-
mation was then delivered via dedicated web technology to treat-
ing physicians. RESULTS: Participating physicians enrolled an
average of seven patients in the study. Each physician visited the
website an average of 40 times. Twenty-one percent of these
visits involved the physician reviewing individual patient
responses. Sixty percent of physicians agreed that their under-
standing of the medication and of the condition was improved
by their participation in the study. Sixty-ﬁve percent of patients
reported believing that the wireless handset device was easy to
use, and 71% noted that the screen of the device was acceptable
for reading, navigating and entering information about their con-
dition. CONCLUSIONS: In a small, proof-of-concept study
designed to assess the viability of entirely automated communi-
cations among physicians and patients regarding treatment and
clinical endpoints in Type-2 diabetes, both physicians and
patients were able to use the system without signiﬁcant difﬁculty
and reported favorable experiences with the approach.
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OBJECTIVES: The aim of this study was to project the long term
costs and outcomes of continuous subcutaneous insulin infusion
(CSII) compared with multiple daily injection (MDI) in patients
with type 1 diabetes (T1D) in the UK. METHODS: The CORE
Diabetes Model is a peer-reviewed, validated model that employs
standard Markov/Monte Carlo simulation techniques to describe
the long term incidence and progression of diabetes-related com-
plications. Baseline cohort characteristics were taken from pub-
lished studies of T1D in the UK (mean age 26 years, duration of
diabetes 12 years, 54% male, 90% Caucasian, mean HbA1c
8.68%). Transition probabilities were derived from major dia-
betes clinical studies. Effects associated with CSII and MDI deliv-
